MedTrace Logo

Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)

NCT00662818 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2018-10-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease. Acetaminophen/paracetamol (APAP) will be used as an active comparator in this study. The primary hypothesis of this study is that telcagepant 300 mg is superior to placebo.

Conditions

  • Migraine Disorders
  • Heart Disease
  • Cerebrovascular Accident
  • TIA (Transient Ischemic Attack)
  • Vascular Diseases
  • Peripheral Vascular Diseases

Interventions

DRUG

Telcagepant

Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)

DRUG

Acetaminophen/Paracetamol

Acetaminophen/Paracetamol (500 mg X 2 dosage units)

DRUG

Placebo to Telcagepant

Placebo 300 mg soft gel capsules or placebo 280 mg tablet.

DRUG

Placebo to Acetaminophen/Paracetamol

Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-17
Primary Completion
2009-09-02
Completion
2009-09-02

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00662818 on ClinicalTrials.gov